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Sommario 
 
L’aldoso reduttasi (ALR2) è il primo enzima della via dei polioli e catalizza la riduzione da 
glucosio a sorbitolo mediante una reazione NADPH dipendente. Il suo coinvolgimento nelle 
complicanze diabetiche l’ha reso un importante target terapeutico ampiamente studiato al fine di 
limitarle o prevenirle. L’insoddisfacente biodisponibilità o l’imponenza degli effetti collaterali 
osservati per le molecole selezionate in vitro quali possibili inibitori dell’aldoso reduttasi, ha 
impedito l’uso della quasi totalità di tali molecole a scopo terapeutico. Gli studi sulla ALR2 hanno 
rivelato che il glucosio non è l’unico substrato che l’enzima è in grado di trasformare; è infatti 
oramai chiaro il coinvolgimento dell’enzima nei processi di detossificazione di specie idrossi 
aldeidiche altamente tossiche derivanti da fenomeni di perossidazione lipidica, quali il 4-idrossi-2-
nonenale (HNE), che viene ridotto dall’ALR2 a 1,4-diidrossinonene con conseguente abbattimento 
della tossicità. E’ altresì nota la capacità dell’ALR2 di ridurre l’addotto che si genera tra HNE e 
glutatione, con produzione di una specie con caratteristiche pro-infiammatorie. 
Questo studio concerne lo sviluppo di una strategia sperimentale per valutare la possibilità di inibire 
l'attività enzimatica di ALR2 in modo differenziale dipendentemente dal substrato utilizzato, al fine 
di individuare inibitori differenziali dell’aldoso reduttasi, capaci di inibire l’attività reduttasica sul 
glucosio e sull’addotto glutatione-HNE, senza interferire nella sua attività detossificante di 
riduzione del HNE. Lo studio ha inoltre evidenziato come la gliceraldeide, routinariamente 
utilizzata come substrato per la valutazione in vitro degli inibitori dell’ALR2, non possa essere di 
fatto utilizzata per la selezione di molecole inibitrici quando l’obiettivo di queste ultime è quello di 
inibire l’attività di riduzione sul glucosio.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
Aldose reductase (ARL2) is the first enzyme of the polyol pathway and it catalyzes the NADPH-
dependent reduction of glucose to sorbitol. 
This enzyme is a widely investigated therapeutic target in order to limit or prevent the diabetic 
complications related to its activity. 
However, most of the molecules identified as in vitro ALR2 inhibitors are not used as drugs, due to 
their poor in vivo efficacy and onset of adverse side effects. 
Moreover, studies related to ALR2 highlighted that the metabolic activity of this enzyme is not 
limited to glucose, indeed this enzyme can metabolize other substrates: in fact ALR2 is involved in 
the detoxification of aldehyidic species generated from lipid peroxidation, such as 4-hydroxy-2-
nonenal which is reduced to 1,4-dihydroxynonene by ALR2, thus reducing its toxicity. 
It is also well-known the capability of ALR2 to reduce the adduct generated between HNE and 
glutathione (GS-HNE), thus producing a pro-inflammatory molecule (glutathionyl-1,4 
dihydroxynonene (GS-DHN). 
This study deals with the development of an experimental strategy to evaluate the possibility to 
differentially inhibit ALR2 activity depending on the substrate; the main focus is the identification 
of differential inhibitors capable to inhibit the ALR2 catalyzed reduction of D-glucose and GS-
HNE, without affecting the detoxificant activity related to HNE reduction. 
The present study highlighted that D,L glyceraldehyde, the substrate universally used for the in 
vitro evaluation of ALR2 inhibitors, cannot be employed as substrate for the selection of inhibitors, 
when their target is the inhibition of the glucose reduction activity. 
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LIST OF ABBREVIATIONS  
 
AGEs    advanced glycation end-product 
AKR      aldo-keto reductase 
ALR2    aldose reductase 
BSA      bovine serum albumin 
Cys        cysteine 
D,L Gal    D,L glyceraldehyde 
DMSO  dimethyl sulfoxide 
DTT      dithiothreitol 
EDTA   ethylenediaminetetraacetic acid 
Gly        glycine 
GSH      glutathione 
GSSG    glutathione Disulfide 
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HNE     4-hydroxy-2-nonenal 
GS-HNE    4-HNE-glutathione adduct 
GS-DHN   glutathionyl-1,4 dihydroxynonene 
Lys          lysine  
Km          Michaelis-Menten constant 
NADPH  nicotinamide Adenine Dinucleotide Phosphate Hydrogen 
NaH2PO4 sodium phosphate buffer 
Phe         phenilalanine 
ROS       reactive oxygen species 
Ser         serine 
SDH      Sorbitol dehydrogenase 
SDS       Sodium Dodecyl Sulphate 
TEMED N,N,N’,N’ tetra methyl ethylene diamine 
Thr       threonine 
Trp       tryptophan 
Tyr      tyrosine 
Val      valine 
Vmax     maximum velocity 
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Chapter 1 – Introduction 
 
1.1 Lens structure and function 
 
 
The lens is a transparent avascular structure with a biconvex shape having the anterior surface less 
curved than the posterior one. The lens is placed between the iris (anterior face) and the vitreous 
body (posterior face), and is suspended in place by the zonular fibers, which attach to the lens near 
its equatorial line and connect the lens to the ciliary body (Fig.1.1). The equatorial zone is 
mitotically active giving rise to epithelial cells that differentiate into lens fibers moving through the 
anterior and posterior poles; with a further cell division, fibers move toward the centre of the lens to 
form the nuclear region. The lens can be structurally divided in three regions from the outer surface 
to the inner one: capsule, epithelium, fibers (Fig 1.2). 
 
 
 
Fig 1.1 - Eye structure, from http://www.virtualmedicalcenter 
 
The capsule is transparent acellular envelope surrounding the lens, composed of collagen 
synthesized by lens epithelium. 
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The epithelium is a monolayer of cuboidal cells underling the capsule only in the anterior portion of 
lens, responsible for the maintenance of lens osmolarity through the action of Na+/K+ ATPase 
pumps. Moreover, besides collagen synthesis for capsule composition, epithelium serves as 
progenitor for lens fibers, which are constantly produced during the lifetime. This region is 
considered the most metabolically active part of the whole lens. 
The fibers are constituted by long cells tightly packaged, connected to each other through gap 
junctions which reflect the importance of a close net between the large bulk of fiber cells and the 
relatively scant number of metabolically active epithelium cells (Fitzjerald P.J et al., 1985). The 
mature lens fibers lack nucleus, endoplasmic reticulum and mitochondria.  
Two regions can be distinguished on the basis of the fibers age: 
- cortex, the outermost and youngest layer 
- nucleus, the inner and oldest layer of lens fibers (Fig 1.2).  
 
 
Fig 1.2 - lens structure, from http://www.photobiology.info/Roberts.html 
 
Lens cells, together with corneal cells, are responsible for the transmission and focusing of light 
onto the retina; the lens can fulfil this task thanks to its plasticity and transparency. In fact, the lens 
is a dynamic structure since it is able to change its curvature through the action of ciliary muscles; 
the change of curvature is a key event in accommodation phenomena that is at the base of focusing 
ability of the lens. Regarding transparency, this feature is fundamental to maintain refractive power, 
and for this reason mature lens fibers lack light scattering organelles. Both transparency and 
plasticity tend to decrease during aging, thus affecting lens function; for example loss of 
transparency within the lens, via disruption of cells membrane or protein aggregation, results in 
cataract onset. 
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Chapter 2 - Diabetes Mellitus 
 
2.1 General background of diabetes mellitus  
 
 
Diabetes mellitus (DM) is characterized by absolute or relative deficiency of insulin secretion 
and/or insulin action, leading to abnormally high level of blood glucose, i.e. hyperglycemia 
(Lambert P., 2002). Diabetes mellitus is a major threat to global public health. In the year 2000, the 
prevalence of diabetes worldwide was estimated to be 2.8%, which were approximately 171 million 
people of all age groups. The number of people with diabetes is likely to increase to 366 million by 
2030 due to population growth, aging, urbanization, and increasing prevalence of obesity and 
sedentary life style (Wild S. et al., 2004).  
According to the criteria recommended by the National Diabetes Data Group in the United States 
and the World Health Organization (WorldHealthOrganization, 1985), diabetes mellitus can be 
divided into two major subgroups: Type I, or insulin-dependent diabetes mellitus (IDDM) and Type 
II, or non-insulin-dependent diabetes mellitus (NIDDM). IDDM is associated with marked 
deficiency of insulin secretion which is due to an actual loss of β-cell mass. Approximately 5-10% 
of diabetics have IDDM, which is common in children and young adults. In contrast, NIDDM is the 
consequence of a deficiency of insulin action due to abnormalities at the cell surface or within the 
cell. NIDDM patients have considerable preservation of the β-cell mass, which secretes sufficient 
quantities of insulin into the circulation. In addition to the two major subgroups of diabetes mellitus, 
gestational diabetes mellitus (GDM) is a special group of diabetes mellitus, which is recognized in 
females during pregnancy and usually disappears after pregnancy (Alberti et al., 1998; Bennett W.L 
et al., 2009). 
 
 
2.2 Long-term Diabetic Complications 
 
 
Patients with diabetes are at a higher risk for cardiovascular events, including strokes, and show 
accelerated formation of severe atherosclerotic lesions in peripheral, coronary, and cerebral arteries. 
They quickly develop visual impairment and blindness, due to cataract and severe retinopathy, as 
well as terminal renal diseases and different forms of nervous system damage, including impaired 
sensation of pain and physical disability. 
Retinopathy is the most frequent complication of IDDM. After 14 years following diagnosis, almost 
all patients with IDDM developed retinopathy, manifested as microaneurysm and hemorrhage in the 
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retina, with a cumulative incidence of 90% (Klein R. et al., 1984; Palmberg P. et., 1981). The 
prevalence of retinopathy in patients with NIDDM rises from 5% among those with a duration of 
diabetes of less than 5 years to 30%, 45%, and 62% among those with a duration of diabetes of 5 to 
9 years, 10 to 14 years, and 15 or more years, respectively In individuals between 20 to 74 years of 
age in industrialized countries, diabetes mellitus is one of the major causes leading to retinopathy 
and blindness (Lloyd C.E et al., 1991). Moreover, diabetic nephropathy, a disorder affecting the 
function of kidney, manifested initially as a persistent elevation in urinary excretion of albumin and 
subsequently as an increase in excretion of protein, is often associated with the increased morbidity 
and mortality in individuals with diabetes. In patients with IDDM, after a lag of 5 years following 
diabetes onset, risk of nephropathy rises rapidly, peaks during the second decade, and then declines 
(Krolewski A.S et al., 1985). In contrast to IDDM, patients with NIDDM often have persistent 
proteinuria during the first 5 years of diabetes, and the prevalence of persistent proteinuria in 
patients with newly diagnosed NIDDM increases with age (Ballard D.J et al., 1988). Among 
individuals with diabetes mellitus, the prevalence of macrovascular disease is also markedly 
increased. The major manifestations of macrovascular diseases are atherosclerosis of coronary 
arteries, cerebral arteries, and large arteries of the lower extremities. These macrovascular diseases 
are the major cause of mortality and significant morbidity in diabetic population (Pyorala K. et al., 
1987). Furthermore, diabetes mellitus causes chronic, widely distributed lesions in the peripheral 
nerves, resulting in diabetic neuropathy. The most common form of diabetic neuropathy is a distal 
sensory polyneuropathy, with or without motor involvement, affecting fibers in a length-related pattern, 
with longer fibers being more vulnerable (Thomas P.K, 1984). 
 Actually, hyperglycemia is considered to be strictly connected with long term diabetic 
complications through different mechanisms: polyol pathway activation, advanced glycated end 
products (AGE) formation, protein kinase C (PKC) activation, and hexosamine pathway action. 
These mechanisms are especially activated in those tissues that don’t need insulin for the uptake of 
glucose and that, therefore, are exposed to high levels of blood glucose. 
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Figure 2.1 - Pathways Implicated in Diabetic Complications 
(From www. http://bmb.utmb.edu/faculty/ramana/) 
 
2.3 Polyol Pathway 
 
 
The polyol pathway is a metabolic route of glucose metabolism alternative to glycolisis, composed 
of two steps. Aldose reductase (ALR2) catalyses the first reaction of the pathway in which glucose 
is reduced to sorbitol, with a parallel oxidation of NADPH to NADP+ .Sorbitol is further oxidized 
into fructose by sorbitol dehydrogenase (SDH) using the cofactor NAD+, which is reduced to 
NADH. 
Aldose reductase has low affinity for glucose and in normal glucose concentrations metabolism of 
glucose through aldose reductase is very small (Brownlee M., 2001). In hyperglycemic conditions 
however, high intracellular glucose increases polyol pathway flux. The result is a large proportion 
of glucose being converted into the polyalcohol and osmolyte, sorbitol. In fact an increased 
intracellular content of sorbitol and fructose has been seen in the lens (Obrosova I.G et al., 1999), 
nerve (Stevens M.J et al., 1994; Obrosova I.G et al., 1999) and retina (Obrosova I.G et al., 2001) of 
diabetic animal models. 
Since there are no specific transporters for sorbitol, it  accumulates inside the cell; Kinoshita 
(Kinoshita J.H et al., 1981) proposed that the accumulation of polyols in the lens would lead to an 
increase in intracellular osmotic pressure, resulting in excessive hydration, gain of Na+, loss of K+ 
ions, and finally leading to a deleterious hyperosmotic swelling . 
The sorbitol accumulation due to the increased flux of glucose through the polyol pathway under 
hyperglycemic conditions is widely accepted as a concausative factor of the onset of diabetic 
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complications; in addition, also the consequent compensatory efflux of other organic osmolytes 
such as myoinositol and the antioxidant taurine (Burg MB et a., 1988; Nakashima E. et al., 2005) 
has  been identified as a relevant component in the complications of diabetes (Franconi F. et al., 
2004; Pop-Busui R. et al., 2001; Schaffer SW., 2009). Conversion of glucose into sorbitol by aldose 
reductase requires the cofactor NADPH, as shown in figure 3. 
Thus, the aldose reductase-mediated depletion of NADPH (the cofactor required for the generation 
of the antioxidant reduced glutathione) results in the decrease of intracellular GSH levels observed 
in many different studies of diabetes (Edwards JL et al., 2008; Brownlee M., 2001; Maritim A.C et 
al., 2003). A restoration of the normal GSH content has been observed in diabetic animals treated 
with aldose reductase inhibitor (Obrosova I.G et al., 2002).  
An increased polyol pathway flux also results in an increase in non-enzymatic glycation, since 
fructose, the endproduct of the pathway, results a glycating agent more potent than glucose. 
Finally increased aldose reductase flux also increases diacylglycerol (DAG) formation increasing 
PKC activation (Edwards J.L et al, 2008). 
 
 
2.4 Advanced Glycated End Products (AGEs) 
 
 
In hyperglycemic conditions the excess of glucose reacts with proteins or blood components, 
increasing the physiological rate of non enzymatic glycation. The advanced glycation end products 
(AGE) formed during spontaneous reaction of aldehydes and proteins, accumulate in tissues and 
modify proteins, thus altering their biological function. 
Therefore they play a crucial role in diseases related to diabetes and aging processes (Y. Al-Abed et 
al., 1999). 
This process is the result of a non enzymatic reaction between  a protein or lipid molecule with a 
sugar molecule, such as fructose or glucose, The first step of formation is the reaction of a 
carbonylic group of glucose and the ε-amino groups of proteins to form an unstable Schiff base. 
Subsequently these Schiff complexes slowly undergo an Amadori adducts. 
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Fig 2.2 - Possible pathways in the formation of advanced glycation end products (AGEs).  
(From: http://cardiovascres.oxfordjournals.org/content/63/4/582/F1.expansion) 
 
Some studies demonstrated that AGEs accumulation accelerates the cataractogenesis process in 
human diabetic lens (Kyselova Z. et al., 2004). 
In diabetic patients, pathologic vascular alterations are strictly linked to the interaction between 
AGEs and different proteins, such as collagen and specific macrophages receptor,  
Therefore AGEs probably contribute to the rapidly progressive atherosclerosis that develops in 
patients with diabetes. In fact, within the atherosclerotic lesion, collagen-linked AGEs bind plasma 
proteins, interact with macrophage receptors to induce cytokine and growth factor release; there is 
also evidence that they modify LDL, making it less susceptible to clearance by LDL receptors 
(Kubiseski T.J et al., 1992). 
AGEs are also able to modify the primary amino group of phospholipids and apo(b) belonging to 
low density lipoproteins (LDL).  
Study of coronary arteries obtained from patients with type 2 diabetes using immunohistochemical 
analysis detected high levels of AGEs reactivity within atherosclerotic plaques stained with anti-
AGE antibodies. This observation is consistent with a link between hyperglycemia, hyperlipidemia, 
and atherosclerosis in diabetes. AGEs formation also contributes to the development of diabetic 
complications by changing the structure and function of the extracellular matrix in the glomerular 
mesangium and elsewhere causing changes in matrix integrity and functions. These alterations 
affect biological functions important to normal vascular tissue integrity supporting the development 
of diabetic complications (Imai N. et al., 1997). 
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2.5 Protein Kinase C (PKC) Activation 
 
 
Intracellular hyperglycaemia has been reported to induce an increase of diacylglycerol (DAG) 
levels in different animal. This increase is directly responsible for the PKC activation observed in 
animal models of diabetes (Koya D. et al., 1998). 
The activation of the PKC pathway is associated with many vascular abnormalities in the retinal, 
renal, and cardiovascular tissues in diabetic and insulin resistant states (Koya D. et al., 1998; 
Derubertis F.R., 1994). PKC activation could affect the functions of several vasoactive factors 
within the kidney like prostaglandins, whose concentration increases causing the release of 
arachidonic acid and leading to an inflammatory response. 
PKC activation results especially deleterious for the retina, in which alteration of blood flow, 
increase vascular permeability, impairment of vascular tone and microaneurysm formation have 
been reported. The resulting ischemia of retinal tissues causes an increase in the expression of 
angiogenic growth factors, such as vascular endothelial growth factor (VEGF), leading to macular 
edema and proliferative retinopathy.  
PKC activation can directly increase permeability of macromolecules across the endothelial or 
epithelial barriers by phosphorylating cytoskeletal proteins or by regulating expression or activity of 
various growth factors. 
Elevated expression of VEGF has been reported in the retina of diabetic patients and animals, thus 
implicated in the neovascularization process of proliferative diabetic retinopathy (Aiello L.P et al., 
1994). 
Another effect of PKC activation is connected with glomerular mesangial matrix expansion and 
capillary basement membrane thickening, characterizing diabetic nephropathy, due to expression of 
extracellular matrix collagen, fibronectin and laminin. Different studies demonstrated that in 
diabetes there is stimulation in the transcription of collagen IV in mesangial cells (Bruneval P. et 
al., 1985; Fukui M. et al., 1992; Cagliero E. et al., 1991). 
 
2.6 Hyperglycemia-induced oxidative stress  
 
 
Free radicals are highly reactive molecules or molecular fragments, characterized by the presence of 
one or more unpaired electrons. They form during the normal cellular function, in particular oxygen 
derived free radicals play an important role in living system (Valko M. et al., 2004). The superoxide 
radical, peroxy radical and hydroxyl radical are the prominent members of the reactive oxygen 
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species (ROS) group, which includes also non radical, but highly oxidising species such as 
hydrogen peroxide. 
Under normal physiological conditions, about 95% of O2 consumed by tissues is utilized in 
metabolic processes, and approximately 5% of the oxygen consumed is transformed into superoxide 
(O2•–) radical, the primary oxygen free radical produced by mitochondria. Superoxide is rapidly 
converted within the cell to hydrogen peroxide (H2O2) by the enzymes superoxide dismutases 
(SOD1, SOD2, and SOD3). In normal conditions catalase, glutathione peroxidase and other 
peroxidases convert hydrogen peroxide into water. However, the presence of transition metal ions 
acting as catalyst, may promote the Fenton reaction in which hydrogen peroxide leads to the 
generation of the more harmful hydroxyl radicals (•OH) (Webster, N.R et al., 1988). 
In addition, some nitrogen compounds such as nitric oxide, peroxynitrite, and their derivatives are 
characterized by a high reactivity; these species are defined as reactive nitrogen species (RNS).   
Superoxide radicals can also react with nitric oxide (NO) to generate the more reactive cytotoxic 
peroxynitrite anions (ONOO–). These latter species can exert direct oxidative modifications through 
one or two electron oxidation processes. They can also damage proteins as well, through the 
formation of nitrotyrosine and lipid oxidation (Huie R.E et al., 1993), after reacting with carbon 
dioxide.  
ROS and RNS can be generated by several sources: 
 the overproduction of superoxide by the mitochondrial electron transport chain (ETC) (Du 
X.L. et al., 2000; Nishikawa T. et al.., 2000); 
 the enzymatic reduction of O2 to superoxide catalyzed by NAD(P)H oxidase(s); 
 NO synthesis catalyzed by nitric oxide synthases (Droge W., 2002); 
 superoxide anion and hydrogen peroxide are produced by the reactions (catalyzed by 
xanthine oxidase) of hypoxanthine to xanthine, and of xanthine to uric acid, respectively 
(Valko M.et al., 2004; Droge W et al., 2002); 
 reactive oxygen species, in particular, superoxide anion and hydrogen peroxide, may be 
produced after the breakdown or uncoupling of the cytochrome P450 catalytic cycle (Droge 
W. et al., 2002); 
 H2O2 is produced by peroxisomes, mainly through the oxidation of fatty acids as a result of 
prolonged starvation besides production under physiologic conditions (Droge W. et al., 
2002); 
 superoxide are produced by activated neutrophils as part of the respiratory burst via the 
action of membrane bound NADPH oxidase on molecular oxygen; 
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 free radical nitric oxide (NO•) is produced by neutrophils; this specie can react with 
superoxide to produce peroxynitrite, itself a powerful oxidant, which may decompose to 
form the hydroxyl radical; 
 a variety of reactive oxygen species, including superoxide anion, nitric oxide and hydrogen 
peroxide is produced by increased oxygen uptake initiated by activated macrophages 
(Conner E.M. et al., 1996); 
 
Under normal physiological conditions, a tight homeostatic balance exists between the formation of 
ROS and RNS and their removal by endogenous antioxidants (Gutteridge J.M.C. et al., 1999). Two 
types of antioxidants can be classified in two classes: non-enzymatic ones and enzymatic ones 
(Halliwell B., 1996). 
Non-enzymatic antioxidants include natural flavonoids, uric acid, bilirubin, albumin, α-tocopherol 
(vitamin E), ascorbic acid (vitamin C), thiol antioxidants (α-lipoic acid, glutathione and 
thioredoxin), a hormonal product of the pineal gland, melatonin and other compounds (McCall M.R 
et al., 1999). Enzymatic antioxidants include the aforementioned catalase, superoxide dismutase, 
and glutathione peroxidase (Mates J.M. et al., 1999). 
Focusing on hyperglycaemic conditions, the overproduction of superoxide anion by the 
mitochondrial electron transport chain (ETC) is considered the primary event which initiates the 
superoxide production (Brownlee M. et al., 2001). This excessive quantity of superoxide is harmful 
for the cell and can generate free radicals and others species such as hydroxyl radical, peroxynitrite 
and hydrogen peroxide which further enhance the toxic effects, damaging the cell in several ways 
(Wallace D.C.,1992). 
Moreover, the adverse effects of superoxide and related species are enhanced in diabetic conditions, 
since defence mechanisms such as superoxide dismutase, catalase, glutathione peroxidase, as well 
as the level of the intracellular antioxidant GSH are substantially compromised (Giacco et al., 
2010). 
This imbalance in the production of ROS is known as oxidative stress and it is involved in many 
pathophysiological pathways related to vascular dysfunction and subsequent diabetic complications 
including, for instance, diabetic retinopathy, nephropathy and neuropathy (Giugliano D. et al., 
1996). 
 
 
 
 
 
 
 
 
 15 
Chapter 3 - Aldose Reductase  
 
3.1 Introduction 
 
 
ALR2 is a small, cytosolic, monomeric protein with  a molecular weight of about 36 kDa, identified 
first in the seminal vesicles by Hers but present in most of mammalian cells (Hers H. G.,1956). It 
belongs to the aldo-keto reductase (AKR) superfamily and catalyzes the NADPH-dependent 
reduction of a wide variety of carbonyl compounds to their corresponding alcohols, exhibiting a 
broad substrate specificity.  
The X-ray crystallographic analysis of the holo-enzyme reveals that ALR2 adopts a Triose 
phosphate IsoMerase (TIM)-barrel conformation, folding up in a typical eight-stranded β/α-barrel to 
which a small β-sheet capping the N-terminal end, residues 2–14, and a C-terminal extension, 
residues 275–315, are added (Bohrani D. W et al.,1992). 
 The active site is located at the C-terminal side of the barrel, deeply buried into it. The cofactor 
binds to ALR2 in an extended conformation, straddling the barrel and projecting its nicotinamide 
moiety to the centre of the protein where it becomes part of the catalytic site (El-Kebbani O. et al., 
1998; Wilson D. K et al., 1992). 
Actually, NADPH transfers the 4-pro-R hydride from the C4 atom of the pyridine ring to the re face 
of the carbonyl group of the substrate, allowing its reduction. Different authors have exhaustively 
described the reaction as a sequential and ordered ensemble of steps, in which NADPH binds first, 
followed by the binding of the aldehyde substrate. After conversion of the aldehyde into alcohol, 
the reaction product is released and the oxidized cofactor disengages from the enzyme. Kinetic and 
spectroscopic experiments showed that both binding and release of NADPH are accompanied by 
conformational changes of the enzyme–cofactor complex, the second modification being the overall 
rate-limiting step of the whole enzymatic cycle (Grimshaw C. E et al., 1990; Kubiseski T. J et al., 
1992; Costantino L et al., 1999). 
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3.2 ALR2 Active Site 
 
 
The catalytic active site of ALR2 is highly hydrophobic. With the only exception of three polar 
residues, namely Gln49, Cys298 and His110, the cavity is bordered by aromatic residues, such as 
Trp20, Tyr48, Trp79, Trp111, Phe121, Phe122 and Trp219, and apolar residues, such as Val47, 
Pro218, Leu300, Leu301. Therefore, ALR2 shows a marked orientation toward lipophilic 
substrates. Considering its compelling role in aldosugar metabolism, such a preference would seem 
rather unusual. 
Actually, D-glucose is a well recognized physiological substrate for ALR2 but it is not the preferred 
one (Kador P. F, 1998). 
The catalytic efficiency showed by the enzyme for its reduction is low, as an apparent Km value 
ranging from 50 to 100 mM testifies, thus suggesting that ALR2 metabolizes this sugar only when 
its concentration increases to pathological levels, such as under diabetic conditions. Extensive 
studies by different research groups (Endo S. et al.,2009) clearly demonstrated that ALR2 is highly 
efficient in reducing short- to long-chain aldehydes, both saturated and unsaturated, aliphatic or 
aromatic, either of exogenous origins or arising in large quantities from lipoproteins and membrane 
phospholipids as a consequence of pathological conditions connected with oxidative stress. ALR2 
also catalyzes the reduction of glutathione conjugates of unsaturated aldehydes, showing in most 
cases efficiency higher than that of the free aldehydes. Moreover, steroid metabolites such as 3,4-
dihydroxyphenylglycoaldehyde, isocorticosteroids, isocaproaldehyde, progesterone and 17α-
hydroxyprogesterone, as well as noradrenalin catabolites, have been identified as further 
endogenous ALR2 substrates (Kumar P.A et al. , 2007; Jez J. M. et al., 1997). 
These findings imply that, besides its role in glucose metabolism, ALR2 plays a significant 
aldehydes removal function, ensuring a complete and efficient elimination of the major electrophilic 
end products of metabolism. As aldehydes exert cytotoxic, mutagenic and carcinogenic activities 
through reaction with biomolecules such as DNA and proteins, ALR2 performs a physiological 
detoxification role. Therefore, under normoglycemic conditions, this enzyme represents a key 
component of the complex antioxidant cell defense system including aldehyde dehydrogenases 
(ALDHs), which catalyzes the oxidation of aldehydes to their corresponding acids, glutathione-S-
transferases (GSTs), which catalyze the conjugation of aldehydes with glutathione, and others aldo-
keto reductases (AKRs), above all aldehyde reductase, ALR1, (EC 1.1.1.2, ALR1), which shows a 
high degree of structural homology with ALR2, possessing a 65% identity in the amino acid 
sequences (El-Kebbani O. et al. ,1998; Kuma P. A. et al., 2007; Chen C.H et al.,2008). 
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The broad substrate specificity shown by ALR2 is achieved through a high degree of plasticity of its 
catalytic binding site. Many crystal structures of ALR2, obtained in the presence of different 
compounds, mainly inhibitors, concurred to prove the ability of ALR2 to modify the conformation 
of this site because of an induced-fit adaptability to the ligand. A careful comparison of these 
conformations led to consider the ALR2 binding site as composed by two distinct portions, 
commonly named ‘anion binding pocket’ and ‘specificity pocket’, endowed with different 
flexibility (Fig 3.1). 
 
 
Fig 3.1 – ALR2 catalitic site 
 
The ‘anion binding pocket’, which is bordered by the pyridine ring of the cofactor and the 
surrounding aminoacids, takes part actively to the catalytic machinery appearing rather stiff. 
Actually, it represents the fixed portion of the site which anchors the ligand, either substrate or 
inhibitor, through its functional group. With the exception of Trp111, which exposes its pi-face to 
the remaining part of the site and shows slight changes in the position of its side chain, residues 
lining the ‘anion binding pocket’, represented by Trp20, Tyr48, Val47, His110, and Trp79, preserve 
their positions quite unaltered across all the known crystal structures of ALR2. On the contrary, the 
so-called ‘specificity pocket’ is highly elastic and shows frequent changes in its conformation. 
Residues going from Val297 to Leu300, the flanking Trp219, Cys303 and Tyr309, and, to a minor 
extent, the far Thr113 and Phe122, host the lipophilic portion of the ligand exhibiting a marked 
adaptation to it. In particular, Leu300 seems to act as a gatekeeper, since, depending on the 
rearrangement of its side chain, as well as on the resulting position of the neighbouring Cys303 and 
Tyr309, makes accessible the ‘specificity pocket’ expanding its width (El-Kebbani O. et al., 2004; 
El-Kebbani O. et al., 2000). 
To date, a number of different conformations of the active binding site have been identified, both 
different and recurrent. The most frequent one is the so called ‘holo-conformation’, shown not only 
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by the holo-enzyme, but also by the enzyme complexed with different ligands such as glucose- 6-
phosphate, cacodylate, citrate, sorbinil, alrestatin and IDD384 (Harrison D.H et al., 1994). For 
instance, the crystallographic structure of the complex between human aldose reductase (ALR2) 
and one of its inhibitors, IDD384, has been solved at 1.7 Å resolution from crystals obtained at pH 
5.0. This structure shows that the binding of the inhibitor's hydrophilic head to the catalytic residues 
Tyr48 and His110 differs from that found previously with porcine ALR2. The difference is 
attributed to a change in the protonation state of the inhibitor (pK(a)=4.52) when soaked with 
crystals of human (at pH 5.0) or pig lens ALR2 (at pH 6.2). This work demonstrates how strongly 
the detailed binding of the inhibitor's polar head depends on its protonation state (Calderone V. et 
al., 2000). 
 
 
3.3 Aldose Reductase Inhibitors (ARI)  
 
 
A large number of molecules have been described to date as ALR2 inhibitors (ARI). Although 
chemically different, they all share common structural features, represented by a polar group (ciclyc 
imide or acetic acid moieties), that binds the active site of ALR2 at the level of the anion binding 
pocket. 
Another common feature is one or more wide lipophilic, aromatic area (i.e. the benzothiazole and 
phthalazinyl groups in zopolrestat etc), which binds in the hydrophobic pocket of ALR2 active site 
through extensive hydrophobic interactions. 
The lipophilic scaffold of the molecule turns out to be oriented within the hydrophobic, highly 
plastic ‘specificity pocket’(Urzhumtsev A. et al., 1997; El-Kabbani O. et al., 1998; Howard E. I. et 
al., 2004). 
Conventionally, the known ARIs are classified into different chemo-types on the basis of the 
ionizable group which allows them to anchor to the catalytic site. Thus, the authors generally refer 
to hydantoin-type inhibitors, such as Sorbinil, Minalrestat, and Ranirestat, and carboxylate-type 
inhibitors, like Tolrestat, Alrestatin, Epalrestat (fig 3.2). 
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Fig. 3.2 - the most famous hydantoin-type ALR2 inhibitors  
 
A third class of ARIs, the so-called flavonoids, includes natural products extracted from plants 
which exploit their hydroxyl functions for a firm anchoring to the catalytic site; see for example 
Quercetin, and Myricetin (Fig 3.3). 
 
 
          
 
Fig. 3.3 - chemical structures of Quercetin, Myricetin 
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In addition, different compounds have been described as ARIs. However, being devoid of the usual 
above-mentioned ionizable functions, they lie outside the ordinary groupage. 
However, despite the impressive number of compounds described as effective ALR2 inhibitors, a 
true and widespread ARI therapy is not yet an established fact, as products that appear to be 
promising during in vitro studies or in trials with animal models often fail to proceed any further, 
showing uncertain results in clinical trials with humans. At present, Epalrestat is the only inhibitor 
in use having reached Japanese market about 15 years ago as a medicine for the treatment of 
diabetic neuropathy and it is still available. 
A fact that could be at least in part responsible for a reduced in vivo efficacy of ARIs is the 
susceptibility of ALR2 to thiol-dependent modifications. In fact the enzyme can be modified by 
physiological disulfides at the level of Cys298, with different effects on the ALr2 activity 
depending on the nature of the disulfide. It is worth noting that conditions of oxidative stress, such 
as exposure of isolated lenses to hyperbaric oxygen, determine an increase of the glutathione-
modified-ALR2 (Cappiello M. et al., 1995; Cappiello M. et al., 2000). These modifications are in 
part held responsible for the reduced efficiency of hydantoine-based ALR2 inhibitors such as 
Sorbinil (Srivastava S.K. et al., 2005; Cappiello M. et al., 1994; Cappiello M. et al, 1996).  
 
 
3.4 Aldose reductase as an aldose/aldehyde reducing enzyme 
 
 
There is unequivocal evidence that ALR2 is an NADPH-dependent aldose reducing catalyst 
enzyme; it came from the stoichiometric relationship between NADPH oxidation and glycerol 
formation from glyceraldehyde in the reaction catalysed by the purified bovine aldose reductase 
(Del Corso A. et al., 2000). 
ALR2, although identified initially as a glucose-reducing enzyme via polyol pathway, is believed to 
be an important component of antioxidant defense system as well as a key mediator of oxidative 
stress-induced molecular signaling. 
Extensive studies by different research groups clearly demonstrated that ALR2 is highly efficient in 
reducing short- to long-chain aldehydes, both saturated and unsaturated, aliphatic or aromatic, either 
of exogenous origins or arising in large quantities from lipoproteins and membrane phospholipids 
because of pathological conditions connected with oxidative stress. ALR2 also catalyzes the 
reduction of glutathione conjugates of unsaturated aldehydes, showing in most cases efficiency 
higher than that of the parent compounds, free aldehydes. Moreover, steroid metabolites such as 3,4 
dihydroxyphenylglycoaldehyde, isocorticosteroids, isocaproaldehyde, progesterone and 17α-
 21 
hydroxyprogesterone, as well as noradrenalin catabolites, have been identified as further 
endogenous ALR2 substrates (Kumar P. A et al., 2007; Jez J. M et al., 1997). 
These findings imply that, besides its role in glucose metabolism, ALR2 plays a significant 
aldehydes removal function, ensuring a complete and efficient elimination of the major electrophilic 
end products of metabolism.As aldehydes exert cytotoxic, mutagenic and carcinogenic activities 
through reaction with biomolecules such as DNA base adducts and proteins, ALR2 performs a 
physiological detoxification role. 
A special role is played by 4-hydroxy-2-nonenal (HNE) and its Michael adduct with GSH: both of 
them are recognized from ALR2 and they are converted to the corresponding alcohols. The 
reduction of HNE to its corresponding alcohol can be considered as a part of the cellular antioxidant 
defence, able to remove a highly toxic aldehydes. On the contrary, the product of reduction of the 
GS-HNE Michael adduct is believed to play a role as pro-inflammatory signal. (Spite M. et al., 
2009). 
Studies in VSMCs cells are reported the involvement ALR2 in NF-kB activation since enzyme 
inhibition significantly prevented cell growth mediated by TNF-alpha (Ramana K.V et al., 2002). 
Similarly, inhibition of ALR2, which is over expressed following stimulation of VSMCs with 
growth factors (Ruef J. et al., 2000) alters the metabolism of HNE, resulting in an attenuation of cell 
proliferation (Ramana K.V et al., 2006). 
Aldose reductase activity is also relevant in the modulation of cell signaling under vascular 
inflammation induced by conditions of hyperglycemia (Ramana K.V.et al., 2004).In this case ALR2 
inhibition significantly prevented NF-kB activation through kinases cascade activation by PKC. 
The observation that ALR2 activity on HNE and/or GSHNE is connected to the mechanism of 
signaling activation of NF-kB is still supported by a series of evidences obtained from human lens 
epithelial cells (HLEC). In fact, apoptosis mediated by NF-kB induced by cultivating these cells in 
the presence of different cell stimuli such as high concentration of glucose or lipopolysaccharide is 
significantly attenuated by treatment of HLECs with inhibitors of ALR2 (Ramana K.V et al., 2003) 
or by silencing the enzyme (Pladzyk A. et al., 2006). 
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Chapter 4 – Materials and methods 
 
4.1. Reagents 
 
 
The following reagents were commercially available: 
 
 NADPH, D,L-glyceraldehyde, D-glucose, urea, sodium azide, HNE-DMA, Methanesulfonic 
acid, dimethylsulfoxide ( DMSO), 1-Methyl-2-phenylindole, Iron chloride (Sigma Aldrich 
Italy)  
 Citric acid (JT Baker) 
 Formaldehyde (Carlo Erba) 
 Sodium phosphate (J.T.Baker) 
 Ammonium sulphate (Merck chemicals) 
 EDTA (Serva Feinbiochemica) 
 Bio Rad protein assay solution (Coomassie brillant blue), 
 GS-HNE (Cayman chemicals) 
 Acrylamide 99.9%, N, N’-methylene-bis- acrylammide, Bio-Rad Protein assay, Silver Stain 
SDS-PAGE molecular weight standards, TEMED (BioRad Laboratories) 
 Matrex Orange A and Ultrafiltration membranes YM30 and YM10 (Millipore, Amicon)  
 Diethylaminoethyl cellulose (DE-52) (Whatman) 
 Dithiothreitol (DTT) (Inalco) 
 Sephadex G75 resin (Pharmacia)  
 MilliQ-Millipore System 
 (S)(+)-6-fluoro-2,3-dihydrospiro[4H-1-benzopyran-4,4′-imidazolidine]-2′,5′-dione (Sorbinil) 
was purchased from Laboratori Baldacci S.p.A., Pisa, Italy.  
 2-[(5Z)-5-[(E)-3-phenil-2-methylprop-2-enylidene]- 4-oxo-2-thioxo-3-thiazolidinyl]acetic 
acid (Epalrestat) was purchased from the Department of Drug Sciences, University of Pisa. 
 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one (Quercetin) was purchased 
from the Department of Drug Sciences, University of Pisa 
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4.2 Laboratory equipment 
 
 
 The pH of buffers was measured with a glass electrode and the basic pHMeter (Denver 
instrument company). 
 Three spectrophotometers: DU-7, DU-6 models (Beckman), Libra S32 PC Biochrom 
(Bioinstruments)  
 Refrigerated centrifuge model J2-21 (Beckman)  
 Mini-PROTEAN® Electrophoresis system and PowerPac® supplies – Biorad 
 Thermostatic bath (Bio-Instruments) 
 
 
4.3 Classes of ALR2 inhibitors 
 
 
The chemical compounds listed below were synthesized by the Department of Drug Sciences of the 
University of Pisa (CFA series, FG series and several amides) or purchased (such as Sorbinil, 
Epalrestat, Quercetin). 
These compounds can be grouped in the following chemical classes and the chemical structures are 
listed in figures from. 4.1 to 4.4: 
 
1)Naphtho[1,2-d]isothiazole Acetic Acid Derivatives , which includes compounds CFA39, CFA40, 
CFA41, CFA42, CFA 44 and CFA35 
2) 1,2,4-oxadiazol-5-yl-acetic acid derivatives which includes compounds CFA32, CFA33, CFA 
34. 
3) Pyrido[1,2-a]pyrimidinone derivatives CFA 1, CFA2, CFA5, CFA23, CFA25, CFA45, CFA8. 
4) pyrazolopyrimidine derivatives which includes the FG compounds. 
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Fig 4.1 - chemical structures of CFA inhibitors 
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Fig 4.2 - chemical structures of FG and SV inhibitors 
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Fig 4.3 - chemical structure of amides inhibitors 
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Fig 4.4 - chemical structure of classical aldose reductase inhibitors 
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4.4 Determination of ALR2 activity  
 
 
The ALR2 activity was determined spectrophotometrically by monitoring the change in absorbance 
at 340 nm, which is due to the oxidation of NADPH catalyzed by the enzyme.  
The enzyme activity during the purification was measured at 37°C, using 4.67 mM D,L 
glyceraldehyde as substrate in 0.25 M sodium phosphate, pH 6.8, 0.38 M ammonium sulfate, 0.11 
mM NADPH, and 0.5 mM EDTA. One Unit of enzyme activity is the amount of enzyme that 
catalyzes the oxidation of 1 µmol/min of NADPH in the above assay conditions. 
The substrate was added to start the reaction, which was monitored for 5 min. The decrease in 
absorbance measured in the absence of substrate was subtracted as a blank. 
The evaluation of the enzymatic activity in the presence of different inhibitor concentrations was 
carried out in the conditions described above using one of the following substrates: 0.11 mM D,L-
glyceraldehyde, 0.11 mM HNE, 0.11 mM GS-HNE or 7 mM D-glucose. 
4.5 Determination of protein content 
 
 
Protein content was evaluated according to Bradford method (Bradford MM, 1976). The assay 
mixture contained in a final volume of 1 mL, 0.2 mL of Bio-Rad Protein assay solution and the 
protein sample. After 15 min at room temperature the absorbance at 595 was measured; the 
absorbance measured for a sample without protein was subtracted as a blank. The protein 
concentration was evaluated referring to a calibration curve (Fig. 4.5) set up using bovine serum 
albumin (BSA) as standard protein. 
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Fig 4.5 - Protein calibration curve using the Bradford method 
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4.6 SDS–PAGE 
 
 
The degree of purity of the final enzymatic preparation as well as that of the samples produced by 
each purification step has been evaluated by means of gel electrophoresis in denatured conditions 
on 12% polyacrilammyde gel according to Laemmli method (Laemmli U.K. 1970). Mini protean kit 
was used as support for gel preparation.  
Gels were run at a constant current of 20 mA per gel, with a running time of 55 minutes.  
The Wray method (Wray W. et al.,1981) was used to visualize proteins: the gel was soaked in 50 mL 
of a solution obtained by adding AgNO3 (0.4 g in 2 mL of water) drop by drop to 10.5 mL of 0.36% 
NaOH containing 0.5 mL of 30% NH3  and brought to the final volume with milliQ water. 
After 15 minutes the gel was washed with water. Subsequently it was transferred into a solution 
which was composed of 0.5 mL of 1% citric acid, 50 µL of 38% formaldehyde and water to a final 
volume of 100 mL. 
The coloration was halted at the appropriate time by transferring the gel in the fixing solution of 
(50% methanol in water).  
 
 
4.7 ALR2 Purification 
 
 
Bovine aldose reductase was isolated and purified by following an optimized procedure (Del Corso 
A et al., 1990). 
Calf eyes were obtained from a local abattoir soon after slaughtering; lenses were removed and kept 
frozen at -20°C until used. 
In order to purify aldose reductase, frozen bovine lenses, after incision of the capsule, were 
suspended in 10 mM sodium phosphate buffer  pH 7 (standard buffer), containing 2mM ditiothreitol 
and stirred in an ice cold bath for 1 h. 
The suspension was then centrifuged at 10000xg at 4°C for 40 minutes and the supernatant 
(constituting the crude extract) was collected.  
The ALR2 and the protein content in the crude extract and at different steps of purification are 
reported in Table 4.1.  
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4.8 Ion exchange chromatography 
 
 
To the crude extract DEAE-cellulose (DE-52 Whatman, 73 g, wet weight) previously equilibrated 
in standard buffer with 2 mM DTT was added. The suspension was gently stirred at 4°C to facilitate 
the interaction between the enzyme and the resin. After nearly 40 minutes the suspension was 
filtered through a filter paper on a Buchner funnel equipped with a vacuum pomp.  
The resin was washed with 4 liters of standard buffer containing 2 mM DTT and then with 2 liters 
of standard buffer containing 2 mM DTT and 30 mM NaCl. 
Subsequently the resin was transferred in a chromatographic column (30 x 3,5 cm) and eluted with 
standard buffer containing 2 mM DTT and 30 mM NaCl at a flow-rate of nearly 55 ml/h. 
As the absorbance at 280 nm was reduced to 0.5, a concentration gradient of NaCl ranging from 30 
to 200 mM in standard buffer supplemented with 2 mM DTT was applied to the column. 
The applient gradient was a non-linear one (Fig. 4.6) and it depended by the next equation: 
 
 
 
− Ci = NaCl concentration in the column; 
− C0 = initial concentration in the mixer (30 mM); 
− Ca =initial concentration (reservoir) (200  mM); 
− Vx  = OUT volume (from the riserve); 
− Vmix = constant volume (in the mixer). 
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Fig. 4.6 - Salt concentration in the mixer plotted against eluition volume 
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The enzyme was eluted at a NaCl concentration of approximately 120 mM 
On the collected fractions, (9 ml) the absorbance at 280 nm and the ALR2 activity were evaluated. 
The elution profile of this chromatrographic step is reported in fig 4.7A. 
The fractions displaying aldose reductase activity (AA/min >0,01) were pooled. 
The solution was concentrated and dyalised against standard buffer on an ultrafiltration YM30 
membrane (30000 Da cut off). 
 
4.9 Affinity chromatography 
 
 
The dialysed DEAE pool was applied on a 23x3.5 cm column containing Matrex Orange A resin, 
previously equilibrated in standard buffer at a flow-rate of 25 ml/h. 
The loaded column was preliminary eluted with standard buffer. The absorbance at 280 nm and the 
enzyme activity were evaluated on the collected fractions (6 mL). In the conditions adopted for the 
removal of proteic components which do not interact with the resin, it was possible to observe the 
elution of an enzymatic activity peak with a certain delay after the elution front. These fractions 
were not used in our studies.  
As the absorbance values at 280 nm fit the baseline, 0.1 mM NADPH was added to the elution 
buffer in order to elute the adsorbed enzyme. The fractions containing ALR2 activity eluted upon 
addition of NADPH were subsequently collected and subjected to concentration on Amicon YM10 
membrane up to 7 mL. 
The elution profile of this chromatographic step is reported in fig. 4.7B. 
 
 
4.10 Molecular exclusion chromatography  
 
 
The concentrated “Matrex pool” was applied on a Sephadex G-75 column (80x2,6 cm) previously 
equilibrated in standard buffer containing 2 mM DTT at a flow rate of 15 ml/h. On the collected 
fractions (4 mL) the absorbance at 280 nm and the aldose reductase activity were measured. 
The eluition profile of this chromatrographic step is reported in fig. 4.7C. 
The fractions exhibiting enzymatic activity were pooled and concentrated on a YM10 membrane up 
to final volum of 6 mL.  
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The final enzyme preparation (specific activity 1.2 U/mg) was stored at 4 °C in standard buffer 
supplemented with 2mM DTT. The SDS-PAGE performed on the sample (Fig. 4.8) confirmed that 
the preparation was electrophoretically homogeneous.  
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Fig. 4.7A - elution profile of DE-52 chromatography: The absorbance at 280 nm (--o--), the  
enzymatic activity (  -∆A/min-) and the beginning of the non-linear gradient(           )          
are reported.    
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Fig. 4.7B elution profile of Orange Matrex chromatography. The absorbance at 280 nm (--o--) and 
the enzymatic activity (  -∆A/min-) are reported. 
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Fig. 4.7C - elution profile of Sephadex G-75 chromatography. The absorbance at 280 nm (--o--) and 
the enzymatic activity (  -∆A/min-) are reported. 
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Fig. 4.8 - SDS PAGE of aldose reductase 
 
From the left: 
Lane 1 molecular weight standards (kDa) 
Lane 2 Purified ALR2 
Lane 3 Enzymatic preparation obtained from Matrex Orange A 
Lane 4 Enzymatic preparation obtained from DEAE cellulose  
Lane5 Crude extract 
 
Silver stain SDS page standards were: rabbit muscle phosphorylase b, bovine serum albumin 
(BSA), Ovoalbumin, Bovin carbonic anhydrase, Lysozime. 
 
 Volume 
(ml) 
mg/ml Utot Specific 
activity 
(U/mg) 
 
Yield 
Fold 
purification  
Crude 
extract 
1000 84 25 2,9*10^-4 100 1 
DE-52 30 10 14 0,046 56 153 
Matrex 
Orange 
6,6 1,7 10,8 0,95 43,2 3166 
Sephadex 
G-75 
6 0,98 8,2 1,28 32 4266 
 
Table 4.1 – ALR2 Purification Table 
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Aim 
 
On the basis of the above described double-face activity of ALR2, responsible for  both damaging 
and detoxifying events, it appears relevant to evaluate the possibility of a selective inhibition of 
aldose reductase in order to block sorbitol formation without interfere in HNE reduction. Thus, the 
study here reported was aimed to search for molecules, which differently from classical ARIs, 
which are drawn to impair ALR2 in the reduction of any aldehydic compounds, may be able to 
exert a specific inhibition of aldoses reduction with minimal or null effects on HNE transformation.  
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Chapter 5 - Results and discussion 
 
The hypothesis of the possibility of an intra-site inhibition of ALR2 with the aim  to impair the 
reduction of hydrophylic substrates (i.e. aldoses) without affecting the reduction of hydrophobic 
aldehydes (i.e. HNE) was originally inspired by two principal observations, which came out from 
deep discussion among the research group in which the present thesis developed: 
I. Molecules which are very different in terms of structures are comparably effective as substrates 
for the enzyme. D,L-glyceraldehyde (D,L-Gal) and HNE for instance, despite their extraordinary 
structural diversity display similar kinetic parameters for the enzyme. Data of Figures 5.1a and 
5.1b, which are consistent with literature data (Hayman S. et al.,1965; Endo S .et al., 2009), 
allow to evaluate Km values for D,L-glyceraldehyde and HNE of 40 and 33 µM, respectively. 
Comparable are also the obtained Vmax values of 0.0089 and 0.01 mM/min, respectively.  
II.  ALR2 cannot be considered simply an enzyme with poor specificity, since it is clearly not 
permissive with respect to substrates of the same class. Literature data demonstrate the ability of 
ALR2 to discriminate substrates both among lipid aldehydes (Grimshaw C.E et al,, 1992) as well 
as among aldoses (Cappiello M. et al.,1994). These consideration led to hypothesize for 
structurally different substrates (i.e the hydrophobic lipid aldehydes or the hydrophylic aldoses ) 
the occurrence of a different interactive pathway to correctly allocate into the active site.  This 
difference, indeed, may be the true target to be addressed by an ideal inhibitor able to inhibit 
sorbitol production without interfere with the detoxifying action of the enzyme.  
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Fig. 5.1 - Determination of kinetic parameters of ALR2 through Lineweaver- Burk plot. 
Panel a: D,L-glyceraldehyde as substrate; Panel b: HNE as substrate.  
The conditions of the enzymatic assay are reported in the methods (Chapter 4). 
Data are reported as the mean of at least three independent determinations ± standard deviation. Data 
reported without SD refer to experiments conducted in duplicate. The intercepts of the regression lines of the 
experimental data with the X-axis and Y-axis allow identifying the opposite reciprocal of Km and the 
reciprocal of Vmax, respectively. 
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The above hypothesis of the possibility of an intra-site inhibition of ALR2 with the aim to impair 
the reduction of hydrophylic substrates (i.e. aldoses) without affecting the reduction of hydrophobic 
aldehydes (i.e. HNE) was initially verified using a series of amides. These compounds, either 
purchased or synthesized at the Department of Drug Sciences of the University of Pisa, since their 
similarities with the hydrophylic substrates, could have the potential to especially interfere with 
D,L-glyceraldehyde reduction. The inhibition curves obtained in the presence of D-glyceramide, L-
glyceramide, D-gluconamide, D-arabinamide, L-arabinamide, D-lactamide, L-lactamide and L-
erythronamide are reported in Figures from 5.2 to 5.4. Only D-glyceramide and D-gluconamide are 
able to inhibit the reduction of D,L-glyceraldehde more efficiently with respect to HNE. For D-
glyceramide a maximal difference in the percentual inhibition of 40.5 at a concentration of 25 mM 
was observed; for D-gluconamide the maximal difference in the percentual inhibition account for 
37.4, measured at a concentration of 20 mM. However, the two compounds differently affect HNE 
reduction. In fact, while D-gluconamide does not interfere with HNE reduction, in the presence of 
20 mM D-glyceramide an inhibition of the HNE reduction of approximatively 28.6% occurs. For all 
the other tested amides, very modest differences were observed between their effects on D,L-
glyceraldehyde and HNE reduction. This occurs irrespectively of the absolute efficacy of these 
amides as inhibitors of ALR2 activity. It is worth to note that, unlike what observed for the D-
enantiomer, L-glyceramide appears completely unable to affect ALR2 activity, a fact that indirectly 
confirms the non permissive interaction of the enzyme with molecules (either substrates or ligands). 
A comparison of the ability of the tested amides to act as differential inhibitors is reported in Fig. 
5.5, in which the maximal differences observed between the residual activity measured using D,L-
glyceraldehyde as substrate and the residual activity on HNE are reported. However, the high 
concentration needed to exert their effects, allows to hypothesize for none of the amides, as such, a 
possible utilization as differential ALR2 inhibitors. 
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Fig. 5.2 - Effect of D-glyceramide, D-gluconamide and L-glyceramide on ALR2 catalyzed 
reduction of D,L-Glyceraldehyde and HNE. Data are reported as the mean of at least three 
independent determinations ± standard deviation. 
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Fig. 5.3 - Effect of D-arabinamide and L-arabinamide on ALR2 catalyzed reduction of D,L-
Glyceraldehyde and HNE. Data are reported as the mean of at least three independent 
determinations ± standard deviation. Data reported without SD refer to experiments conducted in 
duplicate. 
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Fig. 5.4 - Effect of D-lactamide, L-lactamide and L-erythronamide on ALR2 catalyzed reduction of D,L-
Glyceraldehyde and HNE. Data are reported as the mean of at least three independent determinations ± 
standard deviation. Data reported without SD refer to experiments conducted in duplicate. 
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Fig. 5.5 - Comparison of the ability of amides to differentially inhibit ALR2. 
The maximal difference in the percentual inhibition between the residual activity in the presence of 
D,L-Glyceraldehyde and the residual activity in the presence of HNE (∆max%) was calculated from 
the data of Figures 5.2-5.4. 
 
The search for ALR2 differential inhibitors was extended to a series of molecule, synthesized at the 
Department of Drug Sciences of the University of Pisa, belonging to different chemical classes, 
whose structures are reported in chapter 4. All the compounds, together with three well known 
aldose reductase inhibitors, i.e. Epalrestat, Sorbinil and Quercetin (whose structures are reported in 
chapter 4) were tested for their ability to act as differential inhibitors. The inhibition curves obtained 
using both D,L glyceraldehyde and HNE as substrates are reported in Figures from 5.6 to 5.17.  
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Fig. 5.6 - Effect of CFA1, CFA2 and CFA5 on ALR2 catalyzed reduction of D,L-Glyceraldehyde and HNE. 
Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.7 - Effect of CFA23, CFA35 and CFA36 on ALR2 catalyzed reduction of D,L-Glyceraldehyde and 
HNE. Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.8 - Effect of CFA37, CFA41 and CFA46 on ALR2 catalyzed reduction of D,L-Glyceraldehyde and 
HNE. Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.9 - Effect of FG35, SV362 and SV363 on ALR2 catalyzed reduction of D,L-Glyceraldehyde and HNE 
Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.10 - Effect of CFA34 and CFA38 on ALR2 with D,L-Glyceraldehyde and HNE. 
Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.11 - Effect of CFA40 and CFA42 on ALR2 catalyzed reduction of D,L-Gal and HNE. 
Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.12 - Effect of CFA8 and CFA25 on ALR2 with D,L-Gal and HNE. 
Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.13 - Effect of CFA39 and CFA45 on ALR2 catalyzed reduction of D,L-Glyceraldehyde and HNE. 
Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.14 - Effect of FG18, FG19 and FG28 on ALR2 catalyzed reduction of D,L-Glyceraldehyde and HNE. 
Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.15 - Effect of FG31 and FG44 on ALR2 catalyzed reduction of D,L-Glyceraldehyde and HNE. 
Data are reported as the mean of at least three independent determinations ± standard deviation. 
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Fig. 5.16 - Effect of FG47, FG48 and FG51 on ALR2 catalyzed reduction of D,L-Glyceraldehyde and HNE. 
Data are reported as the mean of at least three independent determinations ± standard deviation. 
 53 
40
60
80
100
0 2 4 6 8 10
[Quercetin] µM
%
R
e
si
du
a
l a
ct
iv
ity
D,L-Gal HNE
0
20
40
60
80
100
0 2 4 6 8 10
[Sorbinil] µM
%
R
e
si
du
a
l a
ct
iv
ity
D,L-Gal HNE
20
40
60
80
100
0,00 0,02 0,04 0,06 0,08 0,10
[Epalrestat] µM
%
R
e
si
du
a
l a
ct
iv
ity
D,L-Gal HNE
 
Fig. 5.17 - Effect of Quercetin, Sorbinil and Epalrestat on ALR2 catalyzed reduction of D,L-Glyceraldehyde 
and HNE. Data are reported as the mean of at least three independent determinations ± standard deviation. 
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The results obtained confirm the working hypothesis that ALR2 may indeed targeted by molecules 
with different effectiveness on the enzyme activity depending on the substrate the enzyme is 
working on. In fact, tested compounds display different behaviors, which allow making a first 
relevant classification assigning each compound to one of the following groups: 
 
• A - compounds inhibiting at a major extent the D,L-glyceraldehyde reductase activity 
(Figures from 5.6 to 5.9); 
 
• B - compounds inhibiting at a major extent the HNE reductase activity (Figures 5.10 and 
5.11);  
 
• C- compounds inhibiting approximately at the same extent both activities (Figures from 
5.12 to 5.16).  
 
Even though compounds included in the A and B groups are both able to differently affect D,L 
glyceraldehyde and HNE reduction, clearly only those in the A group can be considered useful for 
the purpose of antagonizing the possible deleterious activity of ALR2 (i.e. polyol generation) 
without affecting the detoxification action of the enzyme. 
As reported above for amides, an indication of the potency of a differential inhibitor is the maximal 
difference observed between the percent residual activity using D,L glyceraldehyde and the residual 
activity using HNE. This parameter has been evaluated for all the tested compounds and the values 
are reported in Figure 5.18. However, the absolute effect on the HNE reduction is also relevant. The 
comparison for instance of Epalrestat and CFA46 reveals that these compounds, while having a 
comparable activity as differential inhibitor (Fig. 5.18), affect at a different extent the HNE 
reduction, being the former able to more efficiently inhibit also HNE reduction.  
The above mentioned ability of ALR2 to discriminate among substrates of the same class poses the 
question of the suitability of D,L glyceraldehyde as reference hydrophilic substrate. Thus, since the 
aim for the proposed differential inhibitors is to be used as drugs to impair in vivo the reduction of 
glucose to sorbitol, several of the above mentioned compounds were tested for their ability to 
inhibit ALR2 activity using glucose as substrate. Results are reported in figures from 5.19 to 5.27, 
in which, for a more direct comparison, the data relative to inhibition on the activity of ALR2 on 
D,L glyceraldehyde and HNE (already shown in Figures from 5.6 to 5.17) are again indicated. It 
appears that the susceptibility to inhibition of ALR2 may be significantly different when glucose as 
substrate is used as substrate instead than D,L glyceraldehyde. The maximal difference observed 
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between the percent residual activity using glucose and the percent residual activity using HNE is 
reported in Fig. 5.28. For compounds CFA2 and CFA5 this parameter appears significantly higher 
with respect to the differential inhibition measured between D,L glyceraldehyde and HNE. This is 
even more evident for compounds FG47 and FG31. Infact, the inhibition exerted by these 
compounds on the reduction of D,L glyceraldehyde is comparable, if not identical (in the case of 
FG47 and FG31), to the inhibition exerted on HNE. On the contrary, when glucose is used as 
substrate, these molecules are able to significantly impair the ALR2 activity. This fact strongly 
suggests that the structural similarity in terms of hydrophilic features of the two aldoses (i.e. D,L 
glyceraldehyde and D-glucose) is not sufficient to allow that, as still now usually considered, D,L 
glyceraldehyde can be used as alternative substrate to glucose for the in vitro screening of ALR2 
inhibitors. 
Compounds CFA34 and CFA40, for which a preferential action on HNE reduction with respect to 
D,L glyceraldehyde was observed (figures 5.10-5.10 and 5.18) are able to inhibit the reduction of 
HNE more efficiently also with respect to glucose reduction, 
As shown in Fig. 5.27 both Sorbinil and Epalrestat efficiently inhibit the enzyme acting on glucose 
in a similar fashion to what observed when D,L glyceraldehyde and HNE are substrates for the 
enzyme. This confirms the feature of these molecules to act as classical ALR2 inhibitors but 
excludes for them any possible use as differential inhibitors. 
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Fig. 5.18 - Comparison of the ability of the tested compounds to differentially inhibit ALR2. 
The maximal difference in the percentual inhibition between the residual activity in the presence of D,L-
Glyceraldehyde and the residual activity in the presence of HNE (∆max%) was calculated from the data of 
Figures 5.6-5.17. 
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Fig 5.19 - Effect of CFA2 and CFA5 on ALR2 catalyzed reduction of D-glucose. Data are reported as the 
mean of at least three independent determinations ± standard deviation. Trends of D,L-Gal (dashed line) and 
HNE (continuous line) based on the data in Fig. 5.6 are reported for comparison. 
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Fig 5.20 - Effect of CFA34 and CFA37 on ALR2 catalyzed reduction of D-glucose as substrate.  Data are 
reported as the mean of at least three independent determinations ± standard deviation. Trends of D,L-Gal 
(dashed line) and HNE (continuous line) based on the data in Fig. 5.8 and Fig. 5.10 are reported for 
comparison. 
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Fig 5.21: Effect of CFA40 and CFA41 on ALR2 catalyzed reduction of D-glucose as substrate. Data are 
reported as the mean of at least three independent determinations ± standard deviation. Trends of D,L-
Glyceraldehyde (dashed line) and HNE (continuous line) based on the data in Fig. 5.8 and Fig. 5.11 are 
reported for comparison. 
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Fig 5.22: Effect of FG18 and FG28 on ALR2 catalyzed reduction of D-glucose. Data are reported as the 
mean of at least three independent determinations ± standard deviation. Trends of D,L-Glyceraldehyde 
(dashed line) and HNE (continuous line) based on the data in Fig. 5.14 are reported for comparison. 
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Fig 5.23: Effect of FG31 and FG35 on ALR2 catalyzed reduction of D-glucose. 
Data are reported as the mean of at least three independent determinations ± standard deviation. Trends of 
D,L-Glyceraldehyde (dashed line) and HNE (continuous line) based on the data in Fig. 5.9 and Fig. 5.15 are 
reported for comparison. 
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Fig. 5.24: Effect of FG44 and FG47 on ALR2 catalyzed reduction of D-glucose. Data are reported as the 
mean of at least three independent determinations ± standard deviation. Trends of D,L-Gal (dashed line) and 
HNE (continuous line) based on the data in Fig. 5.15 and Fig. 5.16 are reported for comparison. 
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Fig 5.25: Effect of FG48 and FG51 on ALR2 catalyzed reduction of D-glucose .Data are reported as the 
mean of at least three independent determinations ± standard deviation. Trends of D,L-Glyceraldehyde 
(dashed line) and HNE (continuous line) based on the data in Fig. 5.16 are reported for comparison. 
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Fig 5.26: Effect of SV362 and SV363 on ALR2 catalyzed reduction of D-glucose. Data are reported as the 
mean of at least three independent determinations ± standard deviation. Trends of D,L-Glyceraldehyde 
(dashed line) and HNE (continuous line) based on the data in Fig. 5.9 are reported for comparison. 
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Fig 5.27: Effect of Sorbinil and Epalrestat on ALR2 catalyzed reduction of D glucose . Data are reported as 
the mean of at least three independent determinations ± standard deviation. Trends of D,L-Glyceraldehyde 
(dashed line) and HNE (continuous line) based on the data in Fig. 5.17 are reported for comparison. 
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Fig. 5.28: Comparison of the ability of the tested compounds to differentially inhibit ALR2. The maximal 
difference in the percentual inhibition between the residual activity in the presence of D-glucose and the 
residual activity in the presence of HNE (∆max%) was calculated from the data of Figures 5.19-5.27. 
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As mentioned in paragraph 3.3 , several literature data suggest that the glutathionyl-HNE Michael adduct can 
be reduced by aldose reductase, generating a glutathionyl-1,4-dyhydroxynonane which is able to induce an 
inflammatory response. 
In this regard, a relevant feature of ALR2 differential inhibitors should be the ability to impair not only the 
specific reduction of glucose to sorbitol, but also the reduction of GS-HNE. 
This, without interfering with the ALR2-dependent transformation of HNE. 
Thus, some of the above mentioned compounds were testes for their ability to impair the GS-HNE reduction. 
Results are reported in figures from 5.29 to 5.32, in which for a more direct comparison, the data relative to 
the inhibition of ALR2 activity of D-glucose and HNE (already shown in figures 5.19, 5.21 - 5.24 and 5.26) 
are again indicated. 
The compounds, irrespectively of the difference in their efficacy in affecting D-glucose reduction with 
respect to HNE reduction, differently act on the transformation of GS-HNE. 
In fact while compounds FG47 and CFA2 efficiently inhibit both D-glucose and GS-HNE reduction, with a 
slight effect on HNE reduction, compounds CFA5 and CFA41 appear completely ineffective as inhibitors of 
the transformation of the GS-HNE. 
Finally, compounds FG28 and FG31 partially affect the adduct transformation. 
Special attention needs to be paid to FG18, whose inhibitory action appears rather specific toward the GS-
HNE, being the reduction of D,L glyceraldehyde, D-glucose and HNE only slightly affected. 
This feature of FG18 may be a relevant aspect to be considered to develop anti-inflammatory agents for 
pathologies not involving hyperglycemic conditions. 
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Fig 5.29: Effect of CFA2 and CFA5 on ALR2 catalyzed reduction of GS-HNE. Data are reported as the 
mean of at least three independent determinations ± standard deviation. Trends of HNE and D-glucose based 
on the data in Fig. 5.19 are reported for comparison. 
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Fig 5.30: Effect of CFA41 and FG18 on ALR2 catalyzed reduction of GS-HNE. Data are reported as the 
mean of at least three independent determinations ± standard deviation. Trends of HNE and D-glucose based 
on the data in Fig. 5.21 and 5.22 are reported for comparison. 
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Fig 5.31: Effect of FG28 and FG31 on ALR2 catalyzed reduction of GS-HNE. Data are reported as the mean 
of at least three independent determinations ± standard deviation. Trends of HNE and D-glucose based on 
the data in Fig. 5.21 and 5.22 are reported for comparison. 
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Fig 5.32: Effect of FG35 and FG47 on ALR2 with GS-HNE as substrate.  Data are reported as the mean of at 
least three independent determinations ± standard deviation. Trends of HNE and D-glucose based on the data 
in Fig. 5.23 are reported for comparison. 
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Fig 5.33: Effect of SV362 and SV363 on ALR2 catalyzed reduction of GS-HNE. Data are reported as the 
mean of at least three independent determinations ± standard deviation. Trends of HNE and D-glucose based 
on the data in Fig. 5.24 are reported for comparison 
 
 72 
Conclusions 
 
Aldose reductase (ALR2) has received the attention of a relevant number of research groups for 
something like four decades, with the aim to find powerful and specific inhibitors able to interdict 
its enzymatic activity. The reason of such an experimental effort stands on the proposed role exerted 
by ALR2 in the etiology of diabetic complication. An increased flux of glucose through the polyol 
pathway, leading to the generation of sorbitol and to the reduction of the efficiency of the 
antioxidant defense, represents the damaging event that the inhibition of the enzyme would prevent. 
However, the feature that toxic lipid aldehydes, such as 4-hydroxy-2-nonenal, generated by 
membrane peroxidation processes, are also substrates for the enzyme, poses the question of the real 
benefit for the cell of a loss of the detoxifying ability of ALR2 as a consequence of its inhibition. 
The most favorable therapeutic action that we can imagine for such a complex metabolic situation 
would be to find instruments (inhibitors) able to intervene only on those processes causing (or 
supposed to cause) cell damage, and at the same time preserving the advantageous processes for the 
cell. This study was aimed to verify the fascinating possibility of an intra-site inhibition of aldose 
reductase with the goal of inhibiting the adverse sorbitol accumulation, without interfering in the 
detoxifying removal of 4-hydroxy-2-nonenal. The obtained results clearly indicate that ALR2 
activity may be differently affected by molecules depending on the substrate the enzyme is working 
on. Thus a new approach in the evaluation of molecules to be potentially used in the treatment of 
diabetic complications can be considered. In addition the possibility to verify the ability of different 
molecules to inhibit not only glucose reduction, but also the transformation of the glutathionyl-
hydroxynonenal Michael adduct (without affecting hydroxynonenal reduction), opens the way for 
these molecules to be used as anti-inflammatory drugs. To conclude, these results open a 
completely new approach to target the activity of the enzyme which may be worth to be considered 
also for different target enzymes whenever their action may require a differential inhibition. 
It is finally worth of attention the fact, emerging from the present work, that D,L-glyceraldehyde, 
the substrate universally used to characterize aldose reductase and to in vitro screen for enzyme 
inhibitors, appears absolutely inadequate to absolve its role of glucose mimetic molecule. Thus 
many molecules which are investigated as potential inhibitors of aldose reductase using D,L-
glyceraldehyde, either selected as active inhibitors or discarded as ineffective, may need to be 
revised with a more appropriated methodological approach. 
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